https://www.marketscreener.com/quote/stock/BEIGENE-LTD-46178119/news/BeiGene-Presents-Pivotal-Phase-2-Clinical-Results-of-Zanubrutinib-in-Patients-with-Relapsed-Refracto-28787393/?utm_source=telegram&utm_medium=social&utm_campaign=share